AKT1 and breast carcinoma: To distinguish between these two possibilities, we first verified that additional, structurally-unrelated compounds (that block Akt activity by different mechanisms) also demonstrated similar anti-breast cancer cell activity as MK-2206 when combined with Th1 cytokines.